$3.01
2.03% yesterday
Nasdaq, Nov 25, 10:07 pm CET
ISIN
US3736785078
Symbol
GOVX
Sector
Industry

Geovax Labs Inc Stock price

$3.01
+0.94 45.41% 1M
+1.27 72.99% 6M
-2.41 44.41% YTD
-3.59 54.39% 1Y
-55.19 94.83% 3Y
-386.99 99.23% 5Y
-74,699,996.99 100.00% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.06 2.03%
ISIN
US3736785078
Symbol
GOVX
Sector
Industry

Key metrics

Market capitalization $28.40m
Enterprise Value $19.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.41
P/S ratio (TTM) P/S ratio 9.19
P/B ratio (TTM) P/B ratio 3.05
Revenue (TTM) Revenue $3.09m
EBIT (operating result TTM) EBIT $-24.49m
Free Cash Flow (TTM) Free Cash Flow $-27.24m
Cash position $8.59m
EPS (TTM) EPS $-9.24
P/E forward negative
P/S forward 5.20
EV/Sales forward 3.63
Short interest 3.55%
Show more

Is Geovax Labs Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Geovax Labs Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Geovax Labs Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Geovax Labs Inc forecast:

Buy
100%

Financial data from Geovax Labs Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.09 3.09
-
100%
- Direct Costs 0.10 0.10
43% 43%
3%
2.99 2.99
4,371% 4,371%
97%
- Selling and Administrative Expenses 5.05 5.05
17% 17%
163%
- Research and Development Expense 22 22
22% 22%
723%
-24 -24
0% 0%
-790%
- Depreciation and Amortization 0.10 0.10
43% 43%
3%
EBIT (Operating Income) EBIT -24 -24
0% 0%
-793%
Net Profit -24 -24
2% 2%
-787%

In millions USD.

Don't miss a Thing! We will send you all news about Geovax Labs Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Geovax Labs Inc Stock News

Neutral
Seeking Alpha
13 days ago
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
14 days ago
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024
Neutral
GlobeNewsWire
21 days ago
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024, after the close of U.S. markets. Following the release, management...
More Geovax Labs Inc News

Company Profile

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.

Head office United States
CEO David Dodd
Employees 17
Founded 1988
Website www.geovax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today